IL33 and acute respiratory distress syndrome: In a mouse model of lung inflammation/injury, Fu et al. found that IL-33 levels in serum, BALF, and lung tissue were significantly higher 24 h post-administration than in the control group, suggesting that IL-33 may be a key factor in ARDS development [49].